EANS-Adhoc: SYGNIS Pharma AG SYGNIS Pharma AG announces key results of its
Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Research & Development
15.12.2011
Ad-hoc release
SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the
treatment of Acute Ischemic Stroke
Heidelberg, 15 December 2011 - SYGNIS Pharma AG (Frankfurt: LIOK; ISIN
DE000A1E9B74; Prime Standard) today announces key results of the Phase II
clinical trial (AXIS 2) of AX200 to treat acute ischemic stroke. The key
results on the relevant primary endpoint, using the modified Rankin Scale
(mRS), and secondary endpoint, using the National Institutes of Health Stroke
Scale (NIHSS), show no improvement in patient outcome relative to the placebo-
treated patient. As a result, the study missed its endpoints.
The primary endpoint of significant functional improvement according to mRS
evaluated AX200 treated patients relative to placebo-treated patients. The
study recorded no clinical improvement and did not show any statistically
significant difference. The secondary endpoint of improvement using the NIHSS
relative to placebo-treated patients did also not record a clinically relevant
or statistically significant difference. The randomized, double-blind AXIS 2
trial enrolled 328 patients in 78 centers throughout Europe.
SYGNIS Pharma will continue to analyse the current data set and the new data
that will become available in the weeks ahead. Full data will be available in
Q1 2012.
For further information please contact:
|Dr. Franz-Werner Haas |
|Senior VP Operations |
|Tel: +49 (0) 6221-454 812 |
|Email: franz-Werner.haas@sygnis.de |
### Disclaimer
This publication is intended for information only and constitutes neither an
offer to sell nor an invitation to buy securities. Some statements included in
this press release, relating neither to proven financial results nor other
historical data, should be viewed as forward-looking, i.e. not definite. Such
statements are mainly predictions of future results, trends, plans or goals.
These statements should not be considered to be total guarantees since given
their very nature they are subject to known and unknown risks and
imponderability and can be affected by other factors as a consequence of which
the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly
from the established conclusions or implied predictions contained in such
statements. SYGNIS does not undertake to publicly update or revise these
statements in the light of new information or future results or for any other
reason.
###
Further inquiry note:
|Dr. Franz-Werner Haas |
Senior VP Operations
Tel: +49 (0) 6221-454 812
Email: franz-Werner.haas@sygnis.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
issuer: SYGNIS Pharma AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 (0)6221 454-6
FAX: +49 (0)6221 454-777
mail: contact@sygnis.de
WWW: http://www.sygnis.de
sector: Biotechnology
ISIN: DE000A1E9B74
indexes: CDAX, Prime All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Stuttgart, Düsseldorf, Hannover, München
language: English